> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Outlines Quicker Path for Lexeo Gene Therapy
- URL: https://www.fdaweb.com/fda-outlines-quicker-path-for-lexeo-gene-therapy/
- Published: 2025-10-07T12:00:00.000Z
- Updated: 2026-09-14T15:23:32.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159997

Lexeo Therapeutics says it has received FDA guidance on a potential accelerated approval pathway for its investigational gene therapy LX2006\. The agency says FDA indicated it is open to allowing pooled data from ongoing Phase 1-2 trials and a future pivotal study to support a BLA for accelerated approval, according to the company. The agency also agreed to consider an earlier assessment of the co-primary endpoint — left ventricular mass index (LVMI) — before the earlier proposed 12-month mark, potentially shortening study timelines.

Lexeo plans to begin its pivotal study in the first half of 2026 after receiving protocol finalization. LX2006 has already received breakthrough therapy, orphan drug, fast track, and rare pediatric disease designations.

Meanwhile, just-announced interim clinical data show meaningful improvements in patients with Friedreich ataxia cardiomyopathy. Updated data from two ongoing Phase 1-2 trials involving 16 participants with more than six months of follow-up show sustained or deepening improvements in both cardiac and neurologic function, according to the company. It says that among participants with abnormal baseline LVMI:

- All six achieved LVMI levels within the normal range.
- Mean LVMI decreased 18% at six months and 23% at 12 months, surpassing the 10% reduction threshold agreed upon with FDA.
- Mid- and high-dose cohorts saw even greater improvements, suggesting a dose-dependent effect.